FMBA spoke about the preliminary results of the study "Meflokhina"

This is stated in a message on the FMBA website.

It is noted that against the background of treatment with this drug of 347 patients infected with coronavirus, "78% of patients with moderate to severe conditions have a positive clinical dynamics."

Also, according to computed tomography, they recorded a regression or stabilization of changes in the lung tissue.

The agency added that reliable conclusions about the efficacy and safety of using Mefloquine in patients with coronavirus will be made at the end of a clinical study and a thorough statistical analysis of the material - until May 20. 

Previously, FMBA reported antiviral activity of Mefloquine against COVID-19.